(Leu31,Pro34)-Peptide YY (human)

Cat. No.: HY-P3877: Fiche technique Instruction de manipulation
FAQs
Technical Support

(Leu31,Pro34)-Peptide YY (human) is a Peptide YY (HY-P1514) derivative and is a potent and selective Y₁ agonist with a K_D of 1.0 nM.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

(Leu31,Pro34)-Peptide YY (human) Chemical Structure

CAS No. : 179986-95-9

Size		Stock
MOQ		Minimum order quantity
50 mg		Obtenir un devis
100 mg		Obtenir un devis
250 mg		Obtenir un devis
Other size		Obtenir un devis

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of (Leu31,Pro34)-Peptide YY (human):

(Leu31,Pro34)-Peptide YY (human) TFA

Other Forms of (Leu31,Pro34)-Peptide YY (human):

(Leu31,Pro34)-Peptide YY (human) TFA In-stock

Recommandations en vedette

•Related Small Molecules:

•Related Proteins:

Voir tous les produits spécifiques à Isoform Neuropeptide Y Receptor:

Voir toutes les isoformes

NPY Y₁ receptor NPY Y₂ receptor NPY Y₄ receptor NPY Y₅ receptor

Activité biologique
Pureté et documentation
Références
Avis client

Description

(Leu31,Pro34)-Peptide YY (human) is a Peptide YY (HY-P1514) derivative and is a potent and selective Y₁ agonist with a K_D of 1.0 nM^[1].

IC₅₀ & Target^[1]

NPY Y₁ receptor

1.0 nM (Kd)

NPY Y₂ receptor

670 nM (Kd)

In Vitro

(Leu31,Pro34)-Peptide YY demonstrates high (nM) affinity in rat frontoparietal cortical membrane preparations (Y₁-enriched tissue) and the rabbit saphenous vein (Y₁ in vitro bioassay) but only low affinity in a Y₂-enriched preparation (rat hippocampus)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

(Leu31,Pro34)-Peptide YY (0.1-1 nmol/day; ICV; 14 days) displays anxiolytic and antidepressant effect in rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague Dawley rats weighing 150-170 g, OBX/Sham model^[2]
Dosage:	0.1, 0.3 and 1 nmol/day
Administration:	ICV, for 14 days
Result:	Significantly decreased hyperlocomotion and immobility time in OBX animals. Reversed the deficit in social contacts in OBX animals. Reduced grooming behavior in sham animals.

Masse moléculaire

4292.75

Formule

C₁₉₅H₂₉₆N₅₄O₅₆

CAS No.

179986-95-9

Sequence

Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2

Sequence Shortening

YPIKPEAPGEDASPEELNRYYASLRHYLNLLTRPRY-NH2

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvant et solubilité

In Vitro:

H₂O

Peptide Solubility and Storage Guidelines:

1. Calculate the length of the peptide.

2. Calculate the overall charge of the entire peptide according to the following table:

	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3. Recommended solution:

Overall charge of peptide	Details
Negative (<0)	1. Try to dissolve the peptide in water first. 2. If water fails, add NH₄OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)	1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

Pureté et documentation

Instruction de manipulation (2659 KB)

Références

[1]. Dumont Y, et al. Peptide YY derivatives as selective neuropeptide Y/peptide YY Y1 and Y2 agonists devoided of activity for the Y3 receptor sub-type. Brain Res Mol Brain Res. 1994 Oct;26(1-2):320-4. [Content Brief]

[2]. Morales-Medina JC, et al. Role of neuropeptide Y Y₁ and Y₂ receptors on behavioral despair in a rat model of depression with co-morbid anxiety. Neuropharmacology. 2012 Jan;62(1):200-8. [Content Brief]